Feasibility study of combination Docetaxel, Cisplatin, and S-1 as neoadjuvant chemotherapy for advanced gastric cancer.

Feasibility study of combination Docetaxel, Cisplatin, and S-1 as neoadjuvant chemotherapy for advanced gastric cancer. - Feasibility study of combination Docetaxel, Cisplatin, and S-1 as neoadjuvant chemotherapy for advanced gastric cancer.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005984

Enrollment

Registered

2011-07-15

Start date

2011-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

Treatment with docetaxel (50mg/m2), CDDP (60mg/m2), S-1 (80mg/m2) and trastuzumab (6mg/kg) combination chemotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Written informed consent. 2) Histologically (cytologically) proven gastric cancer. 3) HER2 positive by IHC or FISH method 4) Curative resection possible (cStage IIIA~IIIC ). 5) To have measurable lesions. 6) No prior chemotherapy or no influence of prior therapy. 7) Tolerable function of bone marrow, liver and kidney. 8) LVEF is 50 % and over. 9) PS 0-1. 10) Expected survival for 3 months. 11) Possible oral intake.

Exclusion criteria

Exclusion criteria: 1) History of hypersensitivity to DCS. 2) Contraindication to Docetaxel, CDDP, S-1, G-CSF. 3) Infectious disease. 4) Severe complication. 5) Neuropathy greater than grade 2. 6) Watery diarrhea. 7) Active double cancer. 8) Persons to be pregnant or to make pregnant.

Design outcomes

Primary

Measure	Time frame
feasibility	—

Countries

Japan

Contacts

Public ContactYasushi Sato

Sapporo Medical University School of Medicine Dept. of Internal Medicine(4)

yasushis@sapmed.ac.jp011-611-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026